RegeneRx Biopharmaceuticals Inc. Stock Analysis RGRX

RegeneRx Biopharmaceuticals, Inc. engages in the development of a novel therapeutic peptide, Thymosin beta 4 for tissue and organ protection, repair, and regeneration. The company is headquartered in Glen Echo, Maryland and currently employs 2 full-time employees. The firm has formulated TB4 into three distinct product candidates in clinical development: RGN-259, RGN-352 and RGN-137. RGN-259 is a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology. RGN-259 is in phase three clinical trials in the United States and EU for the treatment of neurotrophic keratitis, an orphan indication. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, organ damage associated with COVID-19, and other medical indications that may be treated by systemic administration. RGN-137 is a topical gel for dermal wounds and reduction of scar tissue. The company has active partnerships in four territories: North America, Europe, China and Pan Asia.